CompanyORMPNasdaqNew York, NY

Oramed, Ltd.

SEC EDGAR ClinicalTrials.gov

DEF 14ASep 25Latest SEC filing, period to Sep 25

Aug 31Latest story

August 2026

Lifeward CEO Mark Grant departs, Josh Hexter named interim chief

Aug 31PeopleLifeward Ltd

July 2026

Lifeward amends notes with Oramed, closes $5.58 million convertible note financing

Jul 7PartnershipLifeward Ltd